問卷

TPIDB > Principal Investigator

Principal Investigator


Taichung Veterans General Hospital (在職)

Division of Others-

Division of Dermatology

Division of General Internal Medicine

Division of Rheumatology

Taipei Veterans General Hospital (在職)

Division of General Internal Medicine

更新時間:2024-05-30

陳信華CHEN, HSIN-HUA
  • Principal Investigator
  • Clinical Trial Experience (year)
  • shc5555@hotmail.com

篩選

List

69Cases

2022-01-12 - 2027-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting5Sites

2023-06-03 - 2026-03-09

Phase I

Active
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Not yet recruiting2Sites

2023-12-01 - 2026-12-28

Phase I

Active
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Not yet recruiting2Sites

2024-12-02 - 2030-12-09

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2024-09-01 - 2026-12-31

Phase II

xxxxxx
  • Condition/Disease

    xxxxxx

  • Test Drug

    amlitelimab

Participate Sites
2Sites

Recruiting2Sites

2023-06-01 - 2026-06-08

Phase III

xxxxxx
  • Condition/Disease

    xxxxxx

  • Test Drug

    Dazodalibep

Participate Sites
4Sites

Recruiting4Sites

2024-01-15 - 2031-06-30

Phase III

A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjögren’s syndrome
  • Condition/Disease

    Hughes syndrome

  • Test Drug

    VAY736/ianalumabVAY736/ianalumab

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2022-12-14 - 2026-01-01

Phase III

Active
A multi-center, randomized, double-blind, active-controlled, therapeutic confirmatory, phase III study to compare and evaluate the efficacy and safety of Epaminurad with Febuxostat in gout patients
  • Condition/Disease

    gout

  • Test Drug

    Epaminurad

Participate Sites
13Sites

Not yet recruiting1Sites

Recruiting12Sites

2007-04-01 - 2011-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2021-10-01 - 2023-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting2Sites

Recruiting1Sites